1. 163PSAKK 21/12: A stratified, multicenter phase II trial of transdermal CR1447 in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer. (13th May 2019) Authors: Vetter, M H F; Rothgiesser, K; Li, Q; Hawle, H; Schönfeld, W; Ribi, K; Riniker, S; von Moos, R; Müller, A; Thürlimann, B Journal: Annals of oncology Issue: Volume 30(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1703PIncidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). (23rd October 2018) Authors: von Moos, R; Hawle, H; Hayoz, S; Cathomas, R; Müller, A; Schmid, S; Pagani, O; Wehrhahn, T; Rauch, D; Anchisi, S; Hermanns, T; Fehr, M; Stoll, S; Bützberger, P; Zweifel, M; Huber, U; Fuhrer, A C; Schär, C; Gillessen, S; Templeton, A J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 288PDPERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207). (23rd October 2018) Authors: Huober, J; Weder, P; Veyret, C; Thürlimann, B; Xyrafas, A; Vanlemmens, L; Guiu, S; Brain, E; Grenier, J; Dalenc, F; Levy, C; Savoye, A M; Müller, A; Membrez-Antonioli, V; Gerard, M A; Lemonnier, J; Hawle, H; Boven, E; Bonnefoi, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). (4th April 2018) Authors: Ruhstaller, T; Thuss-Patience, P; Hayoz, S; Schacher, S; Knorrenschild, J R; Schnider, A; Plasswilm, L; Budach, W; Eisterer, W; Hawle, H; Mariette, C; Hess, V; Mingrone, W; Montemurro, M; Girschikofsky, M; Schmidt, S C; Bitzer, M; Bedenne, L; Brauchli, P; Stahl, M Journal: Annals of oncology Issue: Volume 29:Number 6(2018) Page Start: 1386 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗